Home / Products / Pharma / General / By Brand Name / Cinarzin Plus

Cinarzin Plus

Cinnarizine BP + Dimenhydrinate BP

Cinarzin Plus 20 mg + 40 mg 10X10 Tablet


Cinarzin Plus contains two active ingredients Cinnarizine and Dimenhydrinate. The two substances belong to different groups of medicines. Cinnarizine is part of a group called calcium antagonists. Dimenhydrinate belongs to a group called antihistamines. Both substances work by reducing symptoms of vertigo (a feeling of dizziness or spinning) and nausea (feeling sick). The combination product is more effective than the individual compounds.

Each tablet contains Cinnarizine BP 20 mg & Dimenhydrinate BP 40 mg.

Cinarzin Plus is used for the treatment of various kinds of nausea and vertigo.

Adults: 1 tablet three times daily, to be taken after meals. Children and adolescents under the age of 18 years: Not recommended Elderly: Dosage as for adults.

Drowsiness, dry mouth, headache, and stomach pain may occur. Rare side effects are impaired vision, allergic reactions, light sensitivity, and difficulty in urinating. Other possible reactions which may occur: weight gain, constipation, tightness of the chest, jaundice, worsening of angle-closure glaucoma, uncontrollable movements, unusual excitement and restlessness, severe skin reactions.

Cinnarizine and Dimenhydrinate do not reduce blood pressure significantly; however, it should be used with caution in hypotensive patients. Cinnarizine and Dimenhydrinate should be taken after meals to minimize any gastric irritation. Caution should be exercised when administering Cinnarizine and Dimenhydrinate to patients with Parkinson’s disease.

Dimenhydrinate and cinnarizine should not be used during pregnancy and lactation.

Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either these drugs or of Cinnarizine and Dimenhydrinate. Therefore, it is advisable to avoid these drugs while taking Cinnarizine and Dimenhydrinate.

Store in a cool and dry place. Keep away from light and out of reach of children.

Cinnarizine and Dimenhydrinate should not be used by patients with severe hepatic impairment. Cinnarizine and Dimenhydrinate is contra-indicated in patients with known hypersensitivity to the active substances or to any of the excipients. Cinnarizine and Dimenhydrinate should not be used in patients with angle-closure glaucoma, convulsions, suspicion of raised intracranial pressure, and alcohol abuse or urine retention due to urethroprostatic disorders.

Each commercial box contains 10 x 10’s tablets in Alu-PVC blister strip.